Flerobuterol (INNTooltip International Nonproprietary Name; developmental code name CRL-40827) is a selective β-adrenergic receptor agonist related to salbutamol which was under development for the treatment of major depressive disorder but was never marketed. It is an agonist of the β₁-, β₂-, and β₃-adrenergic receptors. The drug was under development in France by Cephalon and Lafon and reached phase 2 clinical trials prior to its development being discontinued. It was first described in the scientific literature by 1988 and its development was terminated in 2007.